论文部分内容阅读
目的 :评价更昔洛韦 (GCV)体外抗乙肝病毒 (HBV )活性。方法 :应用HBVDNA转染的人肝癌细胞株 (HepG22 .2 .15 ) ,进行GCV体外抗HBV活性的研究。结果 :GCV能明显减少HepG2 2 .2 .15细胞培养上清液中HBsAg、HBVDNA的产生。Southern印迹法分析 :GCV能显著抑制HBV复制中间体 (包括共价闭合环状态DNA) ,而同时该药物对细胞形态、细胞计数及总细胞DNA无明显的影响。结论 :GCV作为新的抗HBV药物 ,具有抑制HBV复制的活性 ,而细胞毒性作用不明显 ,值得临床上进一步推广应用。
Objective: To evaluate the anti-hepatitis B virus (HBV) activity of ganciclovir (GCV) in vitro. Methods: Human hepatocellular carcinoma cell line (HepG22.2.15) transfected with HBVDNA was used to study the anti-HBV activity of GCV in vitro. Results: GCV significantly reduced the production of HBsAg and HBVDNA in HepG2 2 .2.15 cell culture supernatant. Southern blot analysis: GCV significantly inhibited HBV replication intermediates (including covalently closed loop state DNA), while the drug has no significant effect on cell morphology, cell count and total cellular DNA. Conclusion: As a new anti-HBV drug, GCV has the activity of inhibiting the replication of HBV, while its cytotoxicity is not obvious. It is worth to be further popularized and applied clinically.